Physician profile
Gary Wang
NPI 1053382051
$1,580.01
in general payments reported to CMS, 2019-2025
24 companies · $666 in 2025
The $666 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $34.00 · 2022: $28.70 · 2023: $38.90 · 2024: $347 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $304.30 | 2019-2024 | Sublocade |
| Mdd US Operations, LLC | $236.32 | 2019 | |
| Lilly USA, LLC | $150.64 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Shield Therapeutics INC | $149.67 | 2023-2025 | Accrufer |
| Novo Nordisk INC | $87.00 | 2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $70.67 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $67.92 | 2024 | |
| Exact Sciences Corporation | $63.44 | 2025 | The Cologuard Plus Collection Kit |
| Spr Therapeutics, INC | $58.32 | 2025 | Sprint Pns System |
| Abbott Laboratories | $42.84 | 2025 | Freestyle Libre 3 |
| Itf Therapeutics LLC | $40.77 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $39.60 | 2020-2025 | Dysport |
| Mannkind Corporation | $33.65 | 2025 | |
| Sequel Med Tech, LLC | $27.90 | 2025 | Twiist |
| Phathom Pharmaceuticals, INC. | $27.19 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26.31 | 2025 | |
| Inspire Medical Systems, INC. | $25.74 | 2024 | Inspire |
| Ironshore Pharmaceuticals INC. | $24.07 | 2024 | |
| Ibsa Pharma INC. | $19.96 | 2024 | Tirosint, Flector, Licart |
| Pharming Healthcare, INC. | $19.42 | 2025 | Ruconest |
| Pfizer INC. | $18.04 | 2025 | |
| Insulet Corporation | $16.00 | 2024 | Omnipod |
| Fidia Pharma USA INC. | $15.25 | 2022 | |
| Cepheid | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.